 INmune Bio, Inc. NASDAQ: INMB shares traded higher Wednesday afternoon following data out of a trial for the companys Alzheimers drug candidate. The company said its selective dominant-negative tumor necrosis factor inhibitor candidate for the treatment of Alzheimers disease, XPro pegipanermin, was found to decrease multiple species of Phospho Tau and improve neuroimaging biomarkers of myelination in patients with Alzheimers. 